Evidence map›Paper›PMID 42262873›Full record

ArticleJCI insight2026

Single-nucleus RNA sequencing reveals transcriptional heterogeneity in the blastema of favorable-histology Wilms tumor.

Mike Adam, Keri A Drake, Naomi Pode-Shakked, Katherine VandenHeuvel, S Steven Potter, James Geller

Abstract read
In one paragraph

Article in JCI insight, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mike AdamDivision of Experimental Hematology and Cancer Biology, Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
Keri A DrakeDivision of Pediatric Nephrology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Naomi Pode-ShakkedPediatric Nephrology Unit, Dana Dwek Children's Hospital, Tel Aviv Sourasky University Medical Center (Ichilov), Tel Aviv, Israel.
Katherine VandenHeuvelDivision of Pathology and Laboratory Medicine, and.
S Steven PotterDivision of Developmental Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
James GellerDivision of Hematology/Oncology, Department of Pediatrics, Peckham Center for Cancer and Blood Disorders, Rady Children's Hospital, San Diego, California, USA.

Funding

Wilms tumor 1 (Wt1) mutation reveals mechanisms of cell lineage crosstalk in the developing kidneyK08DK131258 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI DRAKE, KERI ANNE · 2022 to 2024
$502k
NIDDK NIH HHS K08 DK131258
6 · The paper itself

Abstract

While Wilms tumors commonly arise from renal precursor cells and maintain features of the developing kidney, recent studies have demonstrated substantial genetic, histologic, and molecular heterogeneity. To further investigate tumor variability as well as unifying features in tumor biology, we performed single-nucleus RNA sequencing (snRNA-seq) on treatment-naive, favorable-histology Wilms tumors utilizing a reference atlas established from tumor-adjacent kidney samples and fetal kidney. Transcriptional profiles of blastemal, stromal, and epithelial components were correlated with tumor histology and demonstrated developmental-lineage plasticity, with PAX2 and PAX8 expression normally restricted to the nephron lineage of the fetal kidney found to be expressed in tumor stroma, as well as the stromal marker POSTN identified in tumor blastema. Further analyses of the blastema show shared transcriptional features with the differentiation trajectory of "uninduced" to "early differentiating" fetal nephron progenitor cells as well as aberrant expression of stromal signatures. A number of pathways from fetal nephron progenitors were maintained in the blastema, including regulation of stem cell maintenance and axonogenesis, whereas other pathways appear enriched in specific tumor samples, demonstrating the ability of snRNA-seq to identify both unifying transcriptional signatures and uncover distinct molecular targets in signaling pathways and/or biological drivers of Wilms tumorigenesis.

Indexed as

Kidney NeoplasmsWilms TumorGene Expression Regulation, NeoplasticHumansKidneyPAX2 Transcription FactorSequence Analysis, RNASingle-Cell Gene Expression AnalysisPAX2 Transcription FactorCancerDevelopmentNephrologyOncology

Identifiers

PMID42262873
PMCPMC13463612

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.